Page 5,481«..1020..5,4805,4815,4825,483..5,4905,500..»

Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development

Posted: Published on April 5th, 2013

SAN DIEGO, CA--(Marketwired - Apr 4, 2013) - Regen BioPharma, Inc. (Regen), a wholly-owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), provided an update on the Company's progress with HemaXellerate and other new developments. Currently, Regen is focused on two core areas: a)The HemaXellerate Program, which is based on treating disorders of blood production; and b) Our cancer immunotherapy Program which leverages specific cells called "dendritic cells" to specifically kill cancer but not healthy tissue. In June 2012 the Company acquired an option to license US patent # 6,821,513 covering use of endothelial cells to stimulate blood cell production.Subsequently Regen has filed patent applications # 61/648898 and # 61/670791 covering stimulation of blood cell production using placental and fat derived cells, respectively. Utilizing these technologies, as well as, results obtained from studies performed at the Torrey Pines Institute for Molecular Medicine by Sophia Khaldoyanidi, M.D., Ph.D., Regen has developed the HemaXellerate product, which is a patient-specific composition of cells that has previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells. Together with opinion leaders from University of Utah, Indiana University, and Cook General Biotechnology, Regen has published a peer-reviewed paper describing preclinical data supporting … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development

They are expensive, unregulated and potentially dangerous . . . Are stem cell facials REALLY worth the $20,000 price …

Posted: Published on April 5th, 2013

By Catherine Townsend PUBLISHED: 17:14 EST, 4 April 2013 | UPDATED: 04:43 EST, 5 April 2013 First it was the liquid facelift; then the vampire facelift. In recent years, nonsurgical options to turn back the clock have multiplied as quickly as the catchy nicknames. Now, as women pay up to $20,000 for stem cell facelifts, the treatment is being hailed as the new Botox. But according to The New York Times, the technology may not be that cutting-edge. Miracle treatment? Stem cell facelifts have been hailed as the new Botox, but some experts question whether they are worth the five-figure price tag (posed by model) While embryonic skin cells can transform into any type of cell, adult stem cells can only regenerate the types of the organ from which they originate. So in a stem cell facelift - not to be confused with the stem cell facial that uses sheep placenta - doctors take stem cell-enriched tissue from fatty areas like the stomach or inner thigh and inject it back into the face. They may also use a centrifuge to separate the cells and add them back into the fat before grafting. Practitioners claim that this process produces better results. … Continue reading →

Comments Off on They are expensive, unregulated and potentially dangerous . . . Are stem cell facials REALLY worth the $20,000 price …

Are stem cell facelifts REALLY worth the $20,000 price tag?

Posted: Published on April 5th, 2013

By Catherine Townsend PUBLISHED: 17:14 EST, 4 April 2013 | UPDATED: 04:43 EST, 5 April 2013 First it was the liquid facelift; then the vampire facelift. In recent years, nonsurgical options to turn back the clock have multiplied as quickly as the catchy nicknames. Now, as women pay up to $20,000 for stem cell facelifts, the treatment is being hailed as the new Botox. But according to The New York Times, the technology may not be that cutting-edge. Miracle treatment? Stem cell facelifts have been hailed as the new Botox, but some experts question whether they are worth the five-figure price tag (posed by model) While embryonic skin cells can transform into any type of cell, adult stem cells can only regenerate the types of the organ from which they originate. So in a stem cell facelift - not to be confused with the stem cell facial that uses sheep placenta - doctors take stem cell-enriched tissue from fatty areas like the stomach or inner thigh and inject it back into the face. They may also use a centrifuge to separate the cells and add them back into the fat before grafting. Practitioners claim that this process produces better results. … Continue reading →

Comments Off on Are stem cell facelifts REALLY worth the $20,000 price tag?

Will cell therapy become a ‘third pillar’ of medicine?

Posted: Published on April 4th, 2013

Public release date: 3-Apr-2013 [ | E-mail | Share ] Contact: Jeffrey Norris jeff.norris@ucsf.edu 415-502-6397 University of California - San Francisco Treating patients with cells may one day become as common as it is now to treat the sick with drugs made from engineered proteins, antibodies or smaller chemicals, according to UC San Francisco researchers. They outlined their vision of cell-based therapeutics as a "third pillar of medicine" in an article published online April 3 in Science Translational Medicine. "Today, biomedical science sits on the cusp of a revolution: the use of human and microbial cells as therapeutic entities," said Wendell Lim, PhD, a UCSF professor and director of the UCSF Center for Systems and Synthetic Biology, and one of the article's co-authors. Cell therapies have the potential to address critical, unmet needs in the treatment of some of the deadliest diseases, including diabetes, cancer and inflammatory bowel diseases, the scientists said. The reason, they said, is that cells can carry out functions that can't be performed by small-molecule drugs produced by Big Pharma, or by targeted drugs developed by biotech firms in the wake of the genetic engineering revolution. For one, cells are adaptable. They can sense their surroundings … Continue reading →

Posted in Cell Therapy | Comments Off on Will cell therapy become a ‘third pillar’ of medicine?

Will cell therapy become a 'third pillar' of medicine?

Posted: Published on April 4th, 2013

Public release date: 3-Apr-2013 [ | E-mail | Share ] Contact: Jeffrey Norris jeff.norris@ucsf.edu 415-502-6397 University of California - San Francisco Treating patients with cells may one day become as common as it is now to treat the sick with drugs made from engineered proteins, antibodies or smaller chemicals, according to UC San Francisco researchers. They outlined their vision of cell-based therapeutics as a "third pillar of medicine" in an article published online April 3 in Science Translational Medicine. "Today, biomedical science sits on the cusp of a revolution: the use of human and microbial cells as therapeutic entities," said Wendell Lim, PhD, a UCSF professor and director of the UCSF Center for Systems and Synthetic Biology, and one of the article's co-authors. Cell therapies have the potential to address critical, unmet needs in the treatment of some of the deadliest diseases, including diabetes, cancer and inflammatory bowel diseases, the scientists said. The reason, they said, is that cells can carry out functions that can't be performed by small-molecule drugs produced by Big Pharma, or by targeted drugs developed by biotech firms in the wake of the genetic engineering revolution. For one, cells are adaptable. They can sense their surroundings … Continue reading →

Posted in Cell Therapy | Comments Off on Will cell therapy become a 'third pillar' of medicine?

Cell Therapy Could Become As Common As Mainstream Medicine

Posted: Published on April 4th, 2013

Image Caption: (Left Image) For some medical applications, cell therapies are better equipped than small-molecule or genetically-engineered drugs. For instance, individually tailored, induced pluripotent stem cells might be used to regenerate damaged organs or tissues. (Right Image) In this example of the advantages of cell therapies, bacteria may be programmed to make an anti-inflammatory molecule and transplanted to the gut to treat inflammatory bowel disease. Credit: Science Translational Medicine April Flowers for redOrbit.com Your Universe Online A new study from the University of California, San Francisco (UCSF) reveals that treating patients with cells may one day become as common as it is now to treat the sick with drugs from engineered proteins, antibodies, or smaller chemicals. The team outlines their vision of cell-based therapy as a third pillar of medicine in an online edition of Science Translational Medicine. Today, biomedical science sits on the cusp of a revolution: the use of human and microbial cells as therapeutic entities, said Wendell Lim, PhD, a UCSF professor and director of the UCSF Center for Systems and Synthetic Biology. According to the scientists, cell therapies have the potential to address critical, unmet needs in the treatment of some of the deadliest diseases. These … Continue reading →

Posted in Cell Therapy | Comments Off on Cell Therapy Could Become As Common As Mainstream Medicine

Side Effects of Statins May Be Tolerable

Posted: Published on April 4th, 2013

Getty Images/Visuals Unlimited Many people stop taking cholesterol-lowering statins due to muscle pain or nausea, but most people are able to resume taking a different type of the same drug. Statins are among the most prescribed medications in the U.S., with one in four Americans over age 45 years relying on the drugs to lower cholesterol, according to the latest government statistics. But recent reports about their side effects, including serious muscle weakness, memory loss and an increased risk of diabetes, prompted many to discontinue the medications, at least temporarily. In a study of more than 107,835 patients prescribed statins between 2000 and 2008, about 20% reported experiencing a side effect such as muscle pain or nausea related to the drugs, and about half of these patients stopped taking the statin. But more than 90% of these patients who started taking statins again, often turning to a different version of the drug, were able to tolerate the medications the second time around. (MORE:FDA Warns Statin Users of Memory Loss and Diabetes Risks) Published in the Annals of Internal Medicine, the findings encourage both patients andphysicians to consider restarting statin therapy, even if side effects lead them to stop for a … Continue reading →

Posted in Drug Side Effects | Comments Off on Side Effects of Statins May Be Tolerable

Experimental sleep drug may cause fewer side effects : Merck study

Posted: Published on April 4th, 2013

By Julie Steenhuysen CHICAGO (Reuters) - A study in rats and monkeys suggests an experimental Merck & Co sleep drug may help induce sleep without causing the memory loss and attention problems sometimes seen in the commonly used drugs Ambien and Lunesta, company researchers said on Wednesday. Experiments in animals suggest Merck's sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said. Insomnia affects about 10 percent of U.S. adults, and roughly a third of these individuals take drugs to help them sleep. Most sleep aids, including Sanofi's Ambien or Sunovion Pharmaceuticals' Lunesta, act on a key neurotransmitter in the brain called GABA. "These treatments work by forcing the brain to go to sleep," said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study. GABA receptors are important to many brain regions, including those important for cognition, which is likely why common sleep aids can cause memory loss and attention problems. "When you hit those, you don't just hit the sleep system," John Renger, executive director and head of neruoscience basic research at Merck and one of the study's authors, … Continue reading →

Posted in Drug Side Effects | Comments Off on Experimental sleep drug may cause fewer side effects : Merck study

Study: Experimental sleep drug may cause fewer side effects

Posted: Published on April 4th, 2013

Bottle of tablets (Ben Richardson) (Reuters) - A study in rats and monkeys suggests an experimental Merck & Co. sleep drug may help induce sleep without causing the memory loss and attention problems sometimes seen in the commonly used drugs Ambien and Lunesta, company researchers said on Wednesday. Experiments in animals suggest Merck's sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said. Insomnia affects about 10 percent of U.S. adults, and roughly a third of these individuals take drugs to help them sleep. Most sleep aids, including Sanofi's Ambien or Sunovion Pharmaceuticals' Lunesta, act on a key neurotransmitter in the brain called GABA. "These treatments work by forcing the brain to go to sleep," said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study. GABA receptors are important to many brain regions, including those important for cognition, which is likely why common sleep aids can cause memory loss and attention problems. "When you hit those, you don't just hit the sleep system," John Renger, executive director and head of neruoscience basic research at Merck and one of the study's … Continue reading →

Posted in Drug Side Effects | Comments Off on Study: Experimental sleep drug may cause fewer side effects

Pharmagen Presents to North Carolina General Assembly at N.C. Bio's Legislative Breakfast

Posted: Published on April 4th, 2013

SILVER SPRING, Md., April 4, 2013 /PRNewswire/ -- Pharmagen, Inc. (PHRX) (the "Company" or "Pharmagen") is excited to announce that it will be presenting its strategic vision on solving the nation's drug shortage crisis to the North Carolina General Assembly at the North Carolina Biosciences Organization (NCBIO) Legislative Breakfast on April 16th. Each year, NCBIO brings together members of the General Assembly to enjoy breakfast with NCBIO members. This invite-only, legislative event will give Pharmagen the opportunity to meet with State Representatives and State Senators to discuss its planned move to North Carolina. RTI International and Kymanox both event sponsors are North Carolina companies integral to implementing the Pharmagen manufacturing strategy. About Pharmagen Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the nation's sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen is meeting the demand of health provider market through dynamic, independent wholesale, compounding, and innovative IT solutions. Nationally focused, Pharmagen is a dynamic distributor of specialty drugs, compounding and admix pharmacy and producer of over-the-counter ("OTC") branded multivitamins to the healthcare provider market. Pharmagen currently functions as a just-in-time source … Continue reading →

Posted in Wholesale Pharmacy | Comments Off on Pharmagen Presents to North Carolina General Assembly at N.C. Bio's Legislative Breakfast

Page 5,481«..1020..5,4805,4815,4825,483..5,4905,500..»